Drug Database
CL

clodronate disodium (Abioklad / Mebonat / Ostac)

✓ Approved

Abiogen Pharma S.p.A. · SLC17A9 · Small Molecule

What is clodronate disodium?

clodronate disodium is a small molecule developed by Abiogen Pharma S.p.A.. It is approved for therapeutic indications via injectable (others) or intraarterial injection or intramuscular (im) injection.

Drug Profile

Brand NamesAbioklad, Mebonat, Ostac
CompanyAbiogen Pharma S.p.A.
Drug ClassSmall Molecule
Molecular TargetSLC17A9
RouteInjectable (Others), Intraarterial Injection, Intramuscular (IM) Injection
StatusApproved
Sources: ClinicalTrials.gov, Abiogen Pharma S.p.A.

Mechanism of Action

Molecular Targets

clodronate disodium acts on 1 molecular target:

SLC17A9solute carrier family 17 member 9 (POROK8, VNUT)
Want deeper analysis?Noah AI can explain complex mechanisms and compare to similar drugs.

Therapeutic Indications

clodronate disodium is developed for 6 unique indications across 3 therapeutic areas.

Therapeutic AreaConditionPhase
Endocrine disordersHypercalcaemia of malignancy✓ Approved
Musculoskeletal and connective tissue disordersMusculoskeletal pain✓ Approved
Musculoskeletal and connective tissue disordersOsteoarthritis✓ Approved
Neoplasms benign, malignant and unspecified (incl cysts and polyps)Cancer pain✓ Approved
Neoplasms benign, malignant and unspecified (incl cysts and polyps)Breast cancerPhase III

+1 more indication available with a free account

Sign up free to view all indications →

Related Research Articles

PubMedCancer research2026-11-09

Tumor Cells Hijack Coagulation Signaling to Enable Immune Escape and Metastatic Dissemination.

Wang Shuang S, Lin Jiliang J, Zhao Zhou-Kai ZK, Zhang Baishen B et al.

Lymph node metastasis (LNM) represents a pivotal event in cancer progression and a major determinant of response to immune checkpoint blockade (ICB). Elucidation of the molecular mechanisms linking metastatic dissemination to immune suppression could identify potential therapeutic targets to improve ICB efficacy. Here, we identified the coagulation initiator tissue factor (F3) as a central regulator bridging tumor metastasis and immune evasion in gastric cancer (GC). F3 was significantly upregulated in LNM-positive tumors and correlated with impaired ICB responsiveness and poor clinical outcome. Mechanistically, the intracellular domain of F3 directly bound eEF1A1 to promote STAT3 phosphorylation and induce CCL20 expression, which selectively recruited CCR6+ regulatory T cells (Tregs) to establish an immunosuppressive microenvironment. Disruption of this F3-eEF1A1-STAT3-CCL20 axis with the clinically approved compound olsalazine disodium served as a compelling preclinical proof-of-concept to potently suppress tumor growth, abrogate Treg infiltration, and restore ICB sensitivity, all without perturbing basal coagulation. These findings redefine F3 from a canonical coagulation initiator to a tumor-intrinsic immunomodulator and reveal a druggable vulnerability that uncouples its oncogenic signaling from hemostasis.

PMID 43002440
Read full article →
PubMedActa crystallographica. Section E, Crystallographic communications2026-11-08

Syntheses and structures of trans-di-aqua-bis(propane-1,3-di-amine-κ2 N,N')nickel(II) salts of two isomeric naphthalene-disulfonates.

Squattrito Philip J PJ, Gianopoulos Christopher G CG

Aqueous reactions of nickel(II) nitrate, propane-1,3-di-amine, and either naphthalene-1,5-di-sulfonic acid or disodium naphthalene-2,6-di-sulfonate produced crystals of trans-di-aqua-bis-(propane-1,3-di-amine-κ2 N,N')nickel(II) naphthalene-1,5-di-sulfonate, (I), and trans-di-aqua-bis-(propane-1,3-di-amine-κ2 N,N')nickel(II) naphthalene-2,6-di-sulfonate, (II), both [Ni(C3H10N2)2(H2O)2](C10H6O6S2), in high yields. (I) crystallizes in the monoclinic space group P21/c while (II) crystallizes in the triclinic space group P1. In both structures, the cation and anion rest on centers of inversion. The nickel cations display trans octa-hedral coordination of two water mol-ecules and two bidentate propane-1,3-di-amine mol-ecules with Ni-O/N bond distances in the ranges 2.0960 (9)-2.1205 (7) Å (I) and 2.1110 (7)-2.1181 (9) Å (II). The packing in both structures features alternating layers of complex cations and naphthalene-disulfonate anions held together by O-H⋯O and N-H⋯O hydrogen bonds between the water and amine groups of the ligands and the sulfonate groups of the anions. These are the first metal salts of naphthalene-1,5-di-sulfonate and naphthalene-2,6-di-sulfonate that contain propane-1,3-di-amine. The packing in (I) and (II) is compared to each other and to those found in other nickel salts of the anions.

PMID 42997408
Read full article →
PubMedClinical case reports2026-11-06

When the Antibiogram Offers Nothing Else: Ceftriaxone-Sulbactam-Disodium EDTA With Intravenous Colistin in Two Neonates With Metallo-β-Lactamase-Producing Acinetobacter baumannii Meningitis.

Puri Naini N, Shubham Shantanu S, Ahmed Syed Moiz SM, Joshi Richa R et al.

Two neonates with metallo-β-lactamase-producing Acinetobacter baumannii meningitis, resistant to every tested alternative, received ceftriaxone-sulbactam-disodium EDTA plus intravenous colistin, which, to our knowledge, represents the first reported neonatal use of this combinations. Cultures were sterilized by day 7; both survived with normal assessments at 3-months. Concomitant colistin precludes attributing the response to either agent.

PMID 42991875
Read full article →
PubMedBiomaterials advances2026-11-06

Dual-layer silk fibroin microneedles with differential solubility for sequential methotrexate release: A topical treatment strategy for psoriasis.

Qi Zhenzhen Z, Xu Weidong W, Wang Hengbing H, Zhu Yuxuan Y et al.

Controlled methotrexate (MTX) delivery remains a challenge in the topical treatment of psoriasis. Herein, a dual-layer silk fibroin (SF) microneedle (MN) patch was fabricated by sequential casting of a methotrexate disodium (MTXNa₂)-containing needle-tip formulation and an MTX-containing backing-layer formulation. Water vapor annealing was used to stabilize the SF matrix, while the solubility difference between the two drug forms was exploited to regulate release. The selected formulation (MTX-Na₂/MTX mass ratio, 2:8) exhibited an initial release phase followed by sustained transdermal permeation, reaching 81.91 ± 1.61% cumulative permeation at 48 h in vitro. Compared with intraperitoneal (IP) injection, MN administration reduced peak plasma MTX concentration from 50.41 ± 6.11 to 20.54 ± 3.53 μg mL-1, delayed the time to peak from 1 to 12 h, and produced a plasma concentration-time area under the curve 2.52 times that of IP injection. In an imiquimod-induced psoriasis mouse model under matched dosing regimens, epidermal thickness was significantly lower in the MN group than in the IP group (38.98 ± 3.82 versus 64.58 ± 4.31 μm). MN treatment also reduced Ki67 and TNF-α expression compared with IP treatment. These findings support the potential of this formulation for sustained MTX delivery and psoriasis treatment.

PMID 42994371
Read full article →
PubMedJournal of colloid and interface science2026-11-06

Facet-engineered (003)-oriented Bi nanosheets for enhanced photoelectrocatalytic formate production.

Zhou Xiaoxia X, Xu Kangli K, Zhang Lifang L, Qiu Wujie W et al.

Photoelectrocatalytic CO2 reduction reaction (PEC CO2RR) offers a promising avenue for the direct and clean conversion of solar energy into chemical fuels. In this work, Bi nanosheets with highly active (003) facets were successfully deposited on p-Si by precisely tuning the concentration of ethylenediaminetetraacetic acid disodium salt (EDTA-2Na) in the electrodeposition solution. In the PEC CO2RR reaction, the optimized photocathode exhibited high selectivity toward formate, with a Faradaic efficiency (FE) exceeding 80% over a wide potential range of -0.6 to -1.2 V vs. the reversible hydrogen electrode (RHE). The photoelectrode also demonstrated super stability, with both current density and product selectivity showing negligible decay during prolonged 10 h electrolysis. Critically, the introduction of the surfactant cetyltrimethylammonium bromide successfully suppressed the growth of the (003) facet in the electrodeposition process, resulting in a marked decrease in formate selectivity. This enhanced performance is attributed to the synergistic effects of the highly active (003) facet and the efficient photogenerated charge separation via the Schottky junction between Bi and p-Si. Besides, the introduction of a light field further increases the interfacial charge density and improves reaction kinetics at a lower overpotential. In situ infrared spectroscopy and density functional theory (DFT) calculations jointly confirm that the reaction proceeds via the critical *OCHO and *COOH intermediate pathway to efficiently produce formate, and the (003) facet possesses strong CO2 adsorption capability and a high driving force for hydrogenation, making it particularly favorable for the formation of the *COOH intermediate. This work proposes a precise facet engineering strategy, offering a new approach to address the key challenges of catalytic selectivity and charge separation efficiency in this system.

PMID 42994022
Read full article →
PubMedKidney international2026-11-05

Ontogenically distinct macrophages occupy discrete kidney niches and contribute to monocyte recruitment in experimental crescentic glomerulonephritis.

Chang Dong-Yuan DY, Sun Zeguo Z, Li Xuezhu X, Cai Wei W et al.

Crescentic glomerulonephritis (cGN) is characterized by aggressive immune-mediated glomerular injury with prominent macrophage accumulation that correlates with disease severity. However, the distinct contributions of kidney-resident macrophages (KRMs) of different ontogenies remain poorly defined. To explore this, we used single-cell RNA sequencing (scRNA-seq), reporter-based bone marrow chimeras, timed clodronate liposome treatment, and chemokine blockade to define the spatiotemporal dynamics and functional roles of macrophage populations in nephrotoxic serum nephritis (NTSN), a model of cGN. ScRNA-seq of total kidney and CD45+ immune cells revealed that proliferating macrophages and infiltrating monocytes expanded sharply by day five and declined by day ten, indicating that local proliferation, in addition to monocyte recruitment, contributes substantially to early macrophage accumulation in NTSN. Two major KRM subpopulations were distinguished by high Ccr2 or Mrc1 expression, consistent with bone marrow and embryonically seeded, self-renewing KRM population, respectively. In Cx3cr1-GFP recipient mice reconstituted with Ccr2-RFP+ donor bone marrow, embryonic-derived GFP+ KRMs were enriched in the outer medulla and corticomedullary region, whereas donor-derived RFP+ monocytes/macrophages preferentially accumulated in the cortex, including within and around the inflamed glomeruli. A timed clodronate liposome regimen that preferentially reduced recipient-retained GFP+ KRMs decreased the cortical accumulation of RFP+ cells, albuminuria, and histologic kidney injury in NTSN mice. Cell-cell communication analysis identified macrophage-associated CCL12 expression, a murine ortholog of human CCL2, as a candidate mediator of cortical CCR2+ monocyte recruitment. CCL12 neutralization reduced cortical monocyte accumulation and ameliorated kidney damage in NTSN mice. These findings indicate that ontogenically distinct and spatially segregated macrophage populations cooperate during early cGN and support further investigation of the CCR2 axis as a therapeutic target for macrophage-mediated kidney injury in cGN.

PMID 42988163
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about clodronate disodium